These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 20644466

  • 1. A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
    Berntorp E, Figueiredo S, Futema L, Pock K, Knaub S, Walter O, Trawnicek L, Römisch J.
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):577-83. PubMed ID: 20644466
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A, Windyga J, Batorova A.
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [Abstract] [Full Text] [Related]

  • 3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J, Berntorp E, Lindvall K, Björkman S.
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [Abstract] [Full Text] [Related]

  • 6. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K.
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [Abstract] [Full Text] [Related]

  • 7. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA, Soto-Padilla J, Bergés-García A, Rodríguez-Zepeda MD, Pompa-Garza MT, Jaloma-Cruz AR.
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J, Plyushch O, Zozulya N, Yatuv R, Dayan I, Bleicher A, Robinson M, Baru M.
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [Abstract] [Full Text] [Related]

  • 11. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K, Walker I, Decker K, Chan AK, Pai MK.
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.
    Gilmore R, Harmon S, Gannon C, Byrne M, O'Donnell JS, Jenkins PV.
    Haemophilia; 2010 Jul 01; 16(4):671-4. PubMed ID: 20148980
    [Abstract] [Full Text] [Related]

  • 14. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S, Folkesson A, Berntorp E.
    Haemophilia; 2007 Jan 01; 13(1):2-8. PubMed ID: 17212717
    [Abstract] [Full Text] [Related]

  • 15. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P, Penka M, Smejkal P, Geierova V, Ovesná P, Brabec P, Cetkovsky P, Kubes R, Mesterton J, Lindgren P.
    Thromb Res; 2012 May 01; 129(5):e233-7. PubMed ID: 22386136
    [Abstract] [Full Text] [Related]

  • 16. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
    Salvagno GL, Astermark J, Lippi G, Ekman M, Franchini M, Guidi GC, Berntorp E.
    Haemophilia; 2009 Jan 01; 15(1):290-6. PubMed ID: 19149855
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation.
    Lubetsky A, Hoffman R, Zimlichman R, Eldor A, Zvi J, Kostenko V, Brenner B.
    Thromb Res; 2004 Jan 01; 113(6):371-8. PubMed ID: 15226091
    [Abstract] [Full Text] [Related]

  • 18. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors.
    Leissinger CA, Becton DL, Ewing NP, Valentino LA.
    Haemophilia; 2007 May 01; 13(3):249-55. PubMed ID: 17498073
    [Abstract] [Full Text] [Related]

  • 19. Prothrombin complex concentrate (Octaplex): a Portuguese experience in 1152 patients.
    Carvalho MC, Rodrigues AG, Conceição LM, Galvão ML, Ribeiro LC.
    Blood Coagul Fibrinolysis; 2012 Apr 01; 23(3):222-8. PubMed ID: 22450543
    [Abstract] [Full Text] [Related]

  • 20. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E, Windyga J, European Wilate Study Group.
    Haemophilia; 2009 Jan 01; 15(1):122-30. PubMed ID: 19149848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.